ProMIS Neurosciences

About

ProMIS Neurosciences develops therapeutic products and diagnostic devices targeting misfolded protein diseases.

Toronto,Ontario,Canada
1 - 10

Highlights

Details

Last Funding Type: Grant
Last Funding Money Raised: $262.50K
Industries: Biotechnology,Health Diagnostics,Medical,Neuroscience,Therapeutics
Founded date: Jan 1, 2004
Number Of Employee: 1 - 10
Operating Status: Active
Stock Symbol: nasdaq:PMN
Legal Name: ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development-stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

It was founded in 2004 and headquartered in Toronto, Canada.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

17

$9.93M $7.24M

ProMIS Neurosciences has raised a total of $9.93M $7.24M in funding over 2 rounds. Their latest funding was raised on Mar 22, 2021 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Mar 22, 2021	Post-IPO Equity	$7M	—	—	—	Detail
Dec 30, 2019	Post-IPO Equity	—	—	—	—	Detail
May 1, 2018	Post-IPO Equity	$7.24M	—	—	—	Detail
Jul 6, 2017	Grant	$262.50K	—	—	—	Detail
Jun 9, 2016	Post-IPO Equity	$460K	—	—	—	Detail